Therapeutic potential of Momordica charantia L. Extracts on melanoma cells revealed by metabolomic profiling
DOI:
https://doi.org/10.1590/s2175-97902025e24283Keywords:
Momordica charantia L., LC-MS, Metabolomics, MelanomaAbstract
This manuscript evaluates the influence of Momordica charantia L. fruit and seed extracts on B16-F10 melanoma cell lines. The study was concerned with the application of these extracts to the cell lines and subsequent, in comparison to a control group, examination of the resultant metabolite profiles. A comprehensive analysis of metabolites was conducted by employing state-of-the-art Q-TOF LC/MS methodology in which the mature fruit and seed methanol extracts of M. charantia were prepared. The extracts were applied to B16-F10 melanoma cell lines for 48 and 72 hours, after which the cell lines obtained were analyzed using a Q-TOF LC/MS using a C18 column (Poroshell HPH-C18,2.1x100mm,2.7 µm) with a gradient elution program. The raw data obtained was examined using various data analysis methods, and the identified metabolites were reviewed to investigate the potential relationship between the phytochemical components of extract and potential anticancer activity. Certain changes (the levels of L-carnitine, arginine, N-methyltryptamine, sphingosine, prostoglandin, tryptophan and urocanic acid) at the metabolome level were related to potential anti cancer activity and antioxidant activity. This study demonstrated that the fruit and seed extracts of M. charantia induced metabolic changes, associated with anticancer activity, on melanoma cells through distinct pathways.
Downloads
References
Alam S, Asad M, Asdaq SMB, Prasad VS. Antiulcer activity of methanolic extract of Momordica charantia L. in rats. J Ethnopharmacol. 2009;123:464-9.
Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094-1100.
Bayci A, Baker D, Somerset A, Turkoglu O, Hothem Z, Callahan R, et al. Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma. Metabolomics. 2018;14:1-16.
Bhattacharya S, Patel KK, Dehari D, Agrawal AK, Singh S. Melatonin and its ubiquitous anticancer effects. Mol Cell Biochem. 2019;462:133-155.
Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S, et al. Sphingomyelin synthase 1 (SMS1) downregulation is associated with sphingolipid reprogramming and a worse prognosis in melanoma. Front Pharmacol. 2019;10: 443.
Bradford PT. Skin cancer in skin of color. Dermatol Nurs. 2019;21:170.
Chanda J, Biswas S, Kar A, Mukherjee PK. Determination of cucurbitacin E in some selected herbs of ayurvedic importance through RP-HPLC. J Ayurveda Integr Med. 2020;11:287-293.
Chen YC, Gowda R, Newswanger RK, Leibich P, Fell B, Rosenberg G, et al. Targeting cholesterol transport in circulating melanoma cells to inhibit metastasis. Pigment Cell Melanoma Res. 2017;30:541-552.
Costa JGM, Nascimento EM, Campos AR, Rodrigues FF. Antibacterial activity of Momordica charantia (Curcubitaceae) extracts and fractions. J Basic Clin Pharm. 2010;2:45.
De Oliveira MS, da Costa WA, Bezerra FWF, Araújo ME, Ferreira GC, de Carvalho Junior RN. Phytochemical profile and biological activities of Momordica charantia L.(Cucurbitaceae): A review. Afr J Biotechnol. 2018;17:829-846.
Deng Y-Y, Yi Y, Zhang L-F, Zhang R-F, Zhang Y, Wei Z-C, et al. Immunomodulatory activity and partial characterisation of polysaccharides from Momordica charantia. Molecules. 2014;19:13432-47.
Donnelly III D, Aung PP, Jour G. The "-OMICS" facet of melanoma: heterogeneity of genomic, proteomic and metabolomic biomarkers. Semin Cancer Biol. 2019;165-174.
Du Y, Yang J, Su T, Shen Z, Li J. Lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma. Ann Transl Med. 2021;9.
Du Z, Zhang S, Lin Y, Zhou L, Wang Y, Yan G, et al. Momordicoside G Regulates macrophage phenotypes to stimulate efficient repair of lung injury and prevent urethane-induced lung carcinoma lesions. Front. Pharmacol. 2019;10:321.
Dyatlovitskaya E, Kandyba A, Kozlov A, Somova O. Sphinganine in sphingomyelins of tumors and mouse regenerating liver. Biochemistry (Mosc.). 2001;66: 502-4.
Eneş, D, Fidan BB, Başaran AA, Çelebier M. Comparative Plant Metabolomics of Momordica charantia Seeds and Fruits. Rev Bras Farmacogn. 2024;1-6.
Erkekoğlu P, Baydar T. Güncel in vitro sitotoksisite testleri. Hacet Univ J Fac Pharm. 2021;41:45-63.
Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet. 2003;42:941-67.
Fang EF, Froetscher L, Scheibye-Knudsen M, Bohr VA, Wong JH, Ng TB. Emerging antitumor activities of the bitter melon (Momordica charantia). Curr Protein Pept Sci. 2019;20:296-301.
Garg S, Kaul SC, Wadhwa R. Cucurbitacin B and cancer intervention: Chemistry, biology and mechanisms. Int J Oncol. 2018;52:19-37.
Grover JK, Yadav SP. Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol. 2004;93:123-132.
Guevara AP, Lim-Sylianco C, Dayrit F, Finch P. Antimutagens from Momordica charantia. Mutat Res. 1990;230:121-6.
He Q, Li Y, Li H, Zhang P, Zhang A, You L, et al. Hypolipidemic and antioxidant potential of bitter gourd (Momordica charantia L.) leaf in mice fed on a high-fat diet. Pak J Pharm Sci. 2018;31:1837-44.
Honn KV, Meyer J. Thromboxanes and prostacyclin: positive and negative modulators of tumor growth. Biochem. Biophys Res Commun. 1981;102:1122-29.
Huang Z-R, Lin Y-K, Fang J-Y. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules. 2009;14:540-54.
Hubková B, Valko-Rokytovská M, Čižmárová B, Zábavníková M, Mareková M, Birková A. Tryptophan: Its metabolism along the kynurenine, serotonin, and indole pathway in malignant melanoma. Int J Mol Sci. 2022;23:9160.
Izawa K, Amino Y, Kohmura M, Ueda Y, Kuroda M. 4.16-Human–Environment interactions–taste. Compr Nat Prod II. 2010;4:631-71.
Jia S, Shen M, Zhang F, Xie J. Recent advances in Momordica charantia: functional components and biological activities. Int J Mol Sci. 2017;18: 2555.
Joseph B, Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis. 2013;3: 93-102.
Kanehisa M. The KEGG database. In 'In silico'simulation of biological processes: Novartis Foundation Symp. 2002;247:91-103. Wiley Online Library.
Kaplan O, Çelebier M. Evaluation of recent data processing strategies on Q-TOF LC/MS based untargeted metabolomics. Mass Spectrom Lett. 2020;11: 1-5.
Kleszczyński K, Böhm M. Can melatonin and its metabolites boost the efficacy of targeted therapy in patients with advanced melanoma? Exp Dermatol. 2020;29:860-3.
Kodra D, Pousinis P, Vorkas PA, Kademoglou K, Liapikos T, Pechlivanis A, et al. Is current practice adhering to guidelines proposed for metabolite identification in LC-MS untargeted metabolomics? A meta-analysis of the literature. J Proteome Res. 2021;21:590-8.
Kole C, Matsumura H, Behera TK. The bitter gourd genome. Springer. 2020.
Krummel TM, Neifeld JP, Taub RN. Effects of dopamine agonists and antagonists on murine melanoma: correlation with dopamine binding activity. Cancer. 1982;49:1178-84.
Laihia JK, Kallio JP, Taimen P, Kujari H, Kähäri V-M, Leino L. Protodynamic intracellular acidification by cis-urocanic acid promotes apoptosis of melanoma cells in vitro and in vivo. J Invest Dermatol. 2010;130:2431-9.
Li J, Wang Y, Huang J, Xu X, Xiang C. Characterization of antioxidant polysaccharides in bitter gourd (Momordica charantia L.) cultivars. Int J Agric Environ Food Sci. 2010;8:117-20.
Liu D. Cancer biomarkers for targeted therapy. Springer. 2019;1-7.
Liu W-B, Wang H-L, Chen L, Tang B, Ke G, Wang S, et al. Cucurbitacin E inhibits cellular proliferation and induces apoptosis in melanoma by suppressing HSDL2 expression. Chin Med. 2022;17:1-11.
Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res. 2012;25:259-74.
Matsui S, Yamane T, Takita T, Oishy Y, Kobayashi-Hattori K. The hypocholesterolemic activity of Momordica charantia fruit is mediated by the altered cholesterol-and bile acid–regulating gene expression in rat liver. Nutr Res. 2013;33:580-5.
Mimeault M, Batra SK. Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol. 2012;3:32.
Misra BB. Data normalization strategies in metabolomics: Current challenges, approaches, and tools. Eur J Mass Spectrom. 2020;26: 165-174.
Moradkhani F, Moloudizargari M, Fallah M, Asghari N, Heidari Khoei H, Asghari MH. Immunoregulatory role of melatonin in cancer. J Cell Physiol. 2020;235:745-57.
Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol. 2010;49: 978-86.
Nataren N, Yamada M, Prow T. Molecular skin cancer diagnosis: Promise and limitations. J Mol Diagn. 2023;25:17-35.
Nicolaou A, Estdale SE, Tsatmali M, Herrero DP, Thody AJ. Prostaglandin production by melanocytic cells and the effect of α-melanocyte stimulating hormone. FEBS Lett. 2004;570:223-6.
Ordóñez YF, González J, Bedia C, Casas J, Abad JL, Delgado A, et al. 3-Ketosphinganine provokes the accumulation of dihydroshingolipids and induces autophagy in cancer cells. Mol BioSyst. 2016;12:1166-73.
Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021;49:388-96.
Patti GJ. Separation strategies for untargeted metabolomics. J Sep Sci. 2011;34:3460-3469.
Poolperm S, Jiraungkoorskul W. An update review on the anthelmintic activity of bitter gourd, Momordica charantia. Pharmacogn Rev. 2017;11:31.
Qiu F, Huang J, Sui M. Targeting arginine metabolism pathway to treat arginine-dependent cancers. Cancer Lett. 2015;364:1-7.
Raina K, Kumar D, Agarwal R. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy. Semin Cancer Biol. 2016;116-29.
Rakholiya K, Vaghela P, Rathod T, Chanda S. Comparative study of hydroalcoholic extracts of Momordica charantia L. against foodborne pathogens. Indian J Pharm Sci. 2014;76:148.
Samadov BS. The use of the medicinal plant Momordica Charantia L in folk medicine. Asian J Pharm Biol Res. 2022;11.
Shivanagoudra SR, Perera WH, Perez JL, Athrey G, Sun Y, Jayaprakasha G, et al. Cucurbitane-type compounds from Momordica charantia: Isolation, in vitro antidiabetic, anti-inflammatory activities and in silico modeling approaches. Bioorg Chem. 2019;87: 31-42.
Sigruener A, Tarabin V, Paragh G, Liebisch G, Koehler T, Farwick M, et al. Effects of sphingoid bases on the sphingolipidome in early keratinocyte differentiation. Exp Dermatol. 2013;22:677-9.
Smith RA, Zhang Q. Peak Pair Pruner: a post-processing software to MS-DIAL for peak pair validation and ratio quantification of isotopic labeling LC-MS (/MS) data. Bioinform Adv. 2023;3:44.
Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov. 2011;5:109-23.
Sun L, Zhang X, Dong L, Zhang C, Guo P, Wu C. The triterpenoids of the bitter gourd (Momordica Charantia) and their pharmacological activities: A review. J Food Compos Anal. 2021;96:103726.
Sur S, Ray RB. Bitter melon (Momordica charantia), a nutraceutical approach for cancer prevention and therapy. Cancers. 2020;12:2064.
Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181-93.
Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology. 2006;214:8-14.
Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44:2963-97.
Wu Y, Li L. Sample normalization methods in quantitative metabolomics. J Chromatogr A. 2016;1430:80-95.
Yoon J-K, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB. Arginine deprivation therapy for malignant melanoma. Clin Pharmacol. 2012;11-19.
Zhang F, Du G. Dysregulated lipid metabolism in cancer. World J Biol Chem. 2012;3:167.
Downloads
Published
Data Availability Statement
Not informed.
Issue
Section
License
Copyright (c) 2025 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
